EAST HANOVER, N.J., Oct. 16, 2012 /PRNewswire/ -- More than five million people in the United States have Alzheimer's disease, and that number is expected to triple by 2050.2 As the prevalence grows, more Americans are becoming caregivers to a loved one with Alzheimer's. Often an unexpected and life-changing role, caregivers can experience health, relationship and financial challenges and may question how to best navigate the journey.3 In a continued commitment to help fill this unmet need, Novartis Pharmaceuticals Corporation and Alzheimer's caregiving advocate and Emmy-winning TV personality Leeza Gibbons have rallied the caregiving community to share their personal, real-world advice and are now empowering other caregivers to learn from each other on AlzheimersDisease.com.
A new video series, Conversations in Caregiving, now available on the site features a profound discussion between Leeza and her extended family. Their caregiving story is told through generational points of view and helps fulfill a promise Leeza made to her mother to help ease the emotional, physical and spiritual burden that so many caregivers experience.
"Caring for my mom over 10 years, I learned how to love someone with Alzheimer's disease without losing myself. But it wasn't easy," said Leeza. "My family and I felt as if we survived an endurance race, but there were still many emotions and topics we had never discussed – until now. We hope by sitting down together and being honest and candid, we can offer others our best lessons and improve their journey."
In addition, the winning advice from the 10 Alzheimer's caregivers of the national Words of Wisdom contest is featured on AlzheimersDisease.com. Among hundreds of entries, the winners were selected by Leeza and an esteemed panel of judges for being the most positive, unique, useful and affordable "words of wisdom" about finding strength and support during the caregiving journey.
"I was honored to participate as a judge for the Words of Wisdom contest and found each and every entry to be truly inspirational," said James Galvin, MD, MPH, Professor of Neurology and Psychiatry at New York University's Langone Medical Center. "When speaking with caregivers I frequently hear about the uncertainty they experience, and the number of entries demonstrates their profound desire to share the relatable and practical advice they have gathered along their journey to help ease the experience for others."
The next installment in the Conversations in Caregiving series is a free live webcast that will continue to bring much needed resources to caregivers. The webcast, being held on November 15 at 8:00 pm ET, will be hosted by Leeza and a panel of experts including Richard Isaacson, MD, Associate Professor of Clinical Neurology at University of Miami Miller School of Medicine and Caring.com Senior Editor Paula Spencer Scott. Nutrition and caregiver stress will be among the topics discussed. Participants can register for the webcast and submit questions in advance, or view and submit questions during the live event at AlzheimersDisease.com.
About Alzheimer's Disease
Alzheimer's disease is a progressive and devastating condition that gradually causes the loss of memory, and complications with thinking and behavior.4 The disease afflicts more than five million people in the United States and also impacts millions more who love and care for these patients.4,5 Currently there is no cure for Alzheimer's, but treatments are available, and research continues surrounding the disease and its causes.6
About Leeza Gibbons
Leeza is the host of two television shows: "America Now" with Bill Rancic and "My Generation" on PBS. An AARP Ambassador of Care and well-known Alzheimer's advocate, she is the co-author of the book Take Your Oxygen First and served as a long-distance caregiver to her mother. In her mother's honor, Leeza founded the Leeza Gibbons Memory Foundation and Leeza's Place, which provide support for caregivers.
The foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "expected," "will," "potential," "can," "may," "would," "recommend," "expected," or similar expressions, or by express or implied discussions regarding potential new business opportunities. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any such business opportunities will develop in the manner, scale or time frame anticipated. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures, and unexpected reimbursement decisions; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 126,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com/.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
1. National Alliance for Caregiving. "Caregiving in the U.S.: Executive Summary." November 2009. Page 17-18.
2. National Institutes of Health. "Aging: Alzheimer's Disease." Available at: http://www.nih.gov/about/discovery/allages/alzheimers.htm. Accessed July 1, 2012.
3. Maria Shriver, Alzheimer's Association. "The Shriver Report. A Women's Nation Takes on Alzheimer's Association." 2010. Page 77.
4. National Institutes of Health. "Alzheimer's Disease Fact Sheet." NIH Publication No. 08-6423. November 2008 (reprinted February 2010). Page 1.
5. Alzheimer's Association, 2012 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia, Volume 8, Issue 2. Page 26.
6. National Institutes of Health. "Alzheimer's Disease Fact Sheet." NIH Publication No. 08-6423. November 2008 (reprinted February 2010). Page 6.
Novartis Media Relations
+1 212 830 2465 (direct)
+1 862 579 8456 (mobile)
Novartis Pharmaceuticals Corporation
+ 1 862 778 8656 (direct)
+ 1 201 400 1854 (mobile)
SOURCE Novartis Pharmaceuticals Corporation